What is Versameb?
Versameb is a biotechnology firm headquartered in Basel, Switzerland, dedicated to pioneering the next generation of RNA therapeutics. The company leverages advanced RNA technology to address a spectrum of unmet medical needs, positioning itself at the forefront of therapeutic innovation. Versameb's primary focus is on developing cutting-edge solutions for healthcare providers and researchers, aiming to redefine the landscape of RNA-based treatments and establish new standards in medical intervention.
How much funding has Versameb raised?
Versameb has raised a total of $18.4M across 2 funding rounds:
Angel/Seed
$12.1M
Angel/Seed
$6.4M
Angel/Seed (2019): $12.1M with participation from Undisclosed
Angel/Seed (2020): $6.4M led by Undisclosed
Key Investors in Versameb
Undisclosed Investors
Undisclosed Investors
Undisclosed Investors
What's next for Versameb?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Versameb. This capital infusion is expected to accelerate the development and commercialization of its RNA therapeutic candidates, potentially expanding its market reach and solidifying its position in the biopharmaceutical industry. The company's strategic focus on innovation in RNA technology suggests a forward-looking approach to tackling complex diseases and improving patient outcomes, positioning Versameb for significant advancements in the coming years.
See full Versameb company page
